Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
about
The MET axis as a therapeutic target.A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cellsTrough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event.The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?The role of the c-Met pathway in lung cancer and the potential for targeted therapy.A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemiaEssential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesChronic Myeloid Leukaemia in The 21st Century.BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cellsDo SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance.Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl.Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients.LncRNA UCA1 in anti-cancer drug resistance.A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin.Theoretical Studies on Pyrazolo[3,4-d]pyrimidine Derivatives as Potent Dual c-Src/Abl Inhibitors Using 3D-QSAR and Docking Approaches.
P2860
Q24609682-99BD704F-4C50-4DE9-8DC9-90E7B181A1C6Q28486933-26671717-8ACC-4483-94C5-C07D9054AA9BQ33394772-0FFB6327-3525-4AE8-AD20-604A83D8BCC8Q33834313-A029C53D-188B-4C70-98C5-82360414D323Q33971155-7270220E-6F7A-4E15-926C-354F3D552D87Q34065399-1AC74F3B-8175-4A54-9141-09F1B32BBFB7Q34167708-06180EF4-9CDB-4F7F-8611-0CA85BD172BBQ35146937-A8D336EA-DCDF-4E2B-BB57-41E18E31BDFCQ35865441-E03B57F7-7F23-4625-8582-7A1B063F7161Q35885308-22AC3FB1-8258-4828-BD3D-81253DD187F5Q35991845-6E3721DC-9D2B-42CE-AB06-C6F34C32F42EQ36508949-FD4C3509-6826-4EB5-AB24-B63217C8E5B1Q36731265-986BB725-7037-4C9E-ADBF-539227127B1AQ37334605-AF84F530-28B5-4ACF-936A-3B917160D56CQ38729618-64DD8045-4B58-4606-9C3E-0061ED5C2D25Q38771802-E3EA4A1C-355F-4B16-9227-E1A68A23A664Q38899401-58567B36-59BD-4876-A6BC-F7C3BA36E5F4Q39253571-D57F5139-DECE-4D1D-AAD1-8D51708903E6Q39440567-8773BA28-6F8F-408C-8F40-F2A16DE0FDDDQ39459749-0B169881-DA6A-4433-84BC-87227D0B740CQ40081650-C063487C-8AA7-4BFD-B8B2-CBB1DA5C0D47Q41673629-96B6D894-18F7-4B36-84AC-77B64CAB2412Q42156766-09E3E72C-0F16-4F42-A64F-0E083F6E7BBFQ42362804-ECB27A20-0F1A-44B5-9E37-CE28840BD593Q43110118-C39C5C64-113A-4066-941D-5FE97A086EA9Q43250891-416B8BC0-BA10-4168-BEF3-619B15A36B94Q44542424-B6829479-4E8C-494A-835E-118F1944FC24Q50436260-4F7D725E-9A3E-4053-A14D-7321E38740CFQ50437578-EA1DE90A-27D7-4109-BD0A-154D5A10D594Q53611498-CD80B10A-1582-4B6E-A705-E8C069E4599D
P2860
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@ast
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@en
type
label
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@ast
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@en
prefLabel
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@ast
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@en
P1476
Novel targeted therapies to ov ...... hronic myeloid leukemia (CML).
@en
P2093
Christoph Walz
Martin Sattler
P304
P356
10.1016/J.CRITREVONC.2005.06.007
P577
2005-10-05T00:00:00Z